Amylyx Pharmaceuticals, Inc.

SecurityAMLX / Amylyx Pharmaceuticals, Inc.
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership702,236 shares
Latest Disclosed Value $ 9,761,080
Qube Research & Technologies Ltd ownership in AMLX / Amylyx Pharmaceuticals, Inc.

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 702,236 shares of Amylyx Pharmaceuticals, Inc. (US:AMLX) valued at $9,761,080 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 412,873 shares of Amylyx Pharmaceuticals, Inc.. This represents a change in shares of 70.09% during the quarter. The current value of the position is $9,269,515 USD.

Qube Research & Technologies Ltd has a history of taking positions in derivatives of the underlying security (AMLX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

AMLX / Amylyx Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 702,236 289,363 70.09 9,761 95.73 0.0109
2026-02-17 2025-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 412,873 245,767 147.07 4,988 119.69 0.0051
2025-11-14 2025-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 167,106 -270,920 -61.85 2,271 -19.13 0.0023
2025-08-14 2025-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 438,026 -504,865 -53.54 2,808 -15.88 0.0029
2025-05-15 2025-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 942,891 162,325 20.80 3,338 13.12 0.0039
2025-02-14 2024-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 780,566 596,672 324.47 2,951 395.80 0.0039
2024-11-14 2024-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 183,894 -605,233 -76.70 596 -60.31 0.0009
2024-08-14 2024-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 789,127 -154,936 -16.41 1,499 -44.09 0.0024
2024-05-14 2024-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 944,063 461,464 95.62 2,681 -62.26 0.0043
2024-02-13 2023-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 482,599 319,889 196.60 7,104 138.44 0.0138
2023-11-13 2023-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 162,710 38,530 31.03 2,979 11.24 0.0078
2023-08-14 2023-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 124,180 92,455 291.43 2,679 187.96 0.0097
2023-05-15 2023-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 31,725 31,725 931 0.0040
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-08-14 2024-06-30 13F AMYLYX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-14 2024-03-31 13F AMYLYX PHARMACEUTICALS COM Put 15,600 44 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.